Karandikar N J, Vanderlugt C L, Eagar T, Tan L, Bluestone J A, Miller S D
Department of Microbiology-Immunology, Interdepartmental Immunobiology Center, Northwestern University Medical School, Chicago, IL 60611, USA.
J Immunol. 1998 Jul 1;161(1):192-9.
B7/CD28-mediated costimulation is a promising target for therapeutic intervention in autoimmune diseases. However, studies addressing the differential functional roles of B7-1 and B7-2 in several autoimmune models have resulted in conflicting data, perhaps due to the temporal dynamics of B7-1 and B7-2 surface expression on different cell types and/or at different sites during an autoimmune response. We examined the temporal expression of B7 costimulatory molecules in the CNS and in various lymphoid organs during the course of murine relapsing-remitting experimental autoimmune encephalomyelitis (R-EAE). Following immunization of SJL mice with the immunodominant proteolipid protein epitope, PLP139-151, surface expression of B7-1 was up-regulated on B cells, T cells, and macrophages, relative to B7-2, on CNS-infiltrating cells and on splenocytes. Similar enhancement in splenic B7-1 expression could be induced in SJL mice by the adoptive transfer of PLP139-151-specific cells or by immunization with CFA alone. These changes were not observed on lymph node cells, including those isolated from lymph nodes draining the immunization site, which maintained the predominant B7-2 expression pattern seen in naive mice. These phenotypic expression patterns correlated with the functional predominance of B7-1 in costimulating T cell activation when employing APCs from the spleen or CNS of mice with ongoing R-EAE, while B7-2 remained functionally predominant on lymph node APCs. Variation of phenotypic expression and functional dominance of costimulatory molecule expression in different lymphoid compartments during an active inflammatory autoimmune response has important implications in immune regulation, autoimmune pathogenesis, and therapeutic strategies.
B7/CD28介导的共刺激是自身免疫性疾病治疗干预的一个有前景的靶点。然而,在几种自身免疫模型中研究B7-1和B7-2的不同功能作用得到的数据相互矛盾,这可能是由于在自身免疫反应期间,不同细胞类型和/或不同部位B7-1和B7-2表面表达的时间动态变化。我们在小鼠复发缓解型实验性自身免疫性脑脊髓炎(R-EAE)过程中,检测了中枢神经系统和各种淋巴器官中B7共刺激分子的时间表达。用免疫显性蛋白脂蛋白蛋白表位PLP139-151免疫SJL小鼠后,相对于B7-2,B7-1在中枢神经系统浸润细胞和脾细胞的B细胞、T细胞和巨噬细胞上的表面表达上调。通过过继转移PLP139-151特异性细胞或仅用弗氏完全佐剂免疫,可在SJL小鼠中诱导脾B7-1表达出现类似增强。在淋巴结细胞上未观察到这些变化,包括从引流免疫部位的淋巴结分离的细胞,其维持了在未免疫小鼠中所见的主要B7-2表达模式。当使用来自患有进行性R-EAE小鼠的脾脏或中枢神经系统的抗原呈递细胞(APC)时,这些表型表达模式与B7-1在共刺激T细胞活化中的功能优势相关,而B7-2在淋巴结APC上仍保持功能优势。在活跃的炎症性自身免疫反应期间,不同淋巴区室中共刺激分子表达的表型变化和功能优势在免疫调节、自身免疫发病机制和治疗策略方面具有重要意义。